Travere Therapeutics Remains Attractive Despite 'Disappointing' Halt on Pegtibatinase Trial, Wedbush Says
Travere Therapeutics Remains Attractive Despite 'Disappointing' Halt on Pegtibatinase Trial, Wedbush Says
韋德布什表示，儘管佩格替巴替那酶試驗被"令人失望"地中止，Travere Therapeutics仍然具有吸引力
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間